Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. - Wikidata - awgldk - TriplyDB

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

http://www.wikidata.org/entity/Q44461877

about

Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer Interval debulking surgery for advanced epithelial ovarian cancer Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer Interval debulking surgery for advanced epithelial ovarian cancer Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer Angiogenesis inhibitors for the treatment of ovarian cancer Optimal primary surgical treatment for advanced epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer Major clinical research advances in gynecologic cancer in 2013 Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Clinical epidemiology of epithelial ovarian cancer in the UK Unexpected gynecologic findings during abdominal surgery Ovarian cancer standard of care: are there real alternatives?Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Advanced ovarian cancer: what should be the standard of care?The role of surgery in advanced epithelial ovarian cancer Major clinical research advances in gynecologic cancer in 2015 Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer Robotic surgery for ovarian cancers: individualization of the surgical approach to select ovarian cancer patients.Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.Immunological parameters as a new lead in the diagnosis of ovarian cancer.Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.Epithelial ovarian cancer - more data, more questions?Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.Ovarian cancer in Manitoba: trends in incidence and survival, 1992-2011.

P2860

Q24186388-EF8CF0FB-414A-445A-947E-6026CDE37BF5 Q24186533-D11A6293-BBD6-493B-A7B5-DFD278C1648D Q24187622-42139CFF-EFAE-46C3-B6A6-F51222F53240 Q24193930-CA0657B9-D1FF-4C29-815E-59ECC8A25151 Q24197813-F5762892-9FC9-42C9-8458-45AB99C08078 Q24200178-9E3FE699-28BB-4850-A355-AFAB40FEBA0D Q24200525-210FF6C6-EB31-46CB-896A-F8EF59183DF5 Q24201686-3319DEBB-E680-4E54-8CD5-97595E0D7650 Q24234292-179DF51E-27E7-435A-9972-550E61AC79ED Q24234923-220696F7-4911-4BBC-AA0D-64A991C28525 Q24236143-1611ED47-E10C-49A1-8936-5470A181915B Q24562146-2E76A25F-2940-49D2-AE8D-4BFF082A488D Q26471403-84C019D0-0E32-46B7-807D-C56EAEC57CD7 Q26771731-C866D264-62F9-42A6-BB69-477734875D3F Q26780387-6F488A47-53A1-42F7-BEBD-1D3F0143C45A Q26822648-239F8A87-4E90-41B4-B3E1-45E9CE23738D Q26828571-239D32F2-4078-4A66-B72B-2D98DD810427 Q26862249-453923E1-6B1C-4360-8FD8-A7498738FCBF Q27021915-6D18C07F-52D0-40A0-9D40-E6C16C5322A3 Q27024235-CE81925B-7340-445B-8508-415AEEA90CF5 Q27852053-1563AC0D-699B-4286-B570-20E3BFAF4F09 Q28067698-F38CCCA4-99AA-4182-B5BD-80983FD21596 Q28077183-5728D0D3-9286-4493-A9FC-F0B09EA473A7 Q28484592-D35D7370-5B02-48DB-BAEC-8B5AE08A429E Q30252115-8151A62C-9E0A-4A38-A692-D7E21914987D Q30253028-1676D71C-7C42-469E-9F67-D9E4798B2E53 Q30360249-A8FE84BE-FF83-4AB6-8111-0E6F5677488B Q30405727-F6BC6BC8-DCFF-442E-9DC3-851526747E45 Q30414037-B7FBB718-C2EB-4510-9CA6-070B98316BFD Q30414045-4FD449AE-3431-47AD-A629-91249B5F13D0 Q30434977-4FE1233C-C75C-4022-8BD0-C73AA0E29DC6 Q30717971-1CFC4130-115E-420B-9198-D99AC5919231 Q30869183-6263346F-1453-44B7-9398-D675A6279027 Q30945812-4F9F6B04-B8BD-44CA-8E0D-6728C49E0139 Q31044907-57DF0DF1-812B-4B57-86CA-F69634141B28 Q33436678-AC0D53C0-A471-4499-9606-E03F20054841 Q33563963-0EFB8CEE-C7C9-45DF-B227-658451236A96 Q33594110-68607637-833F-4BDC-AEDC-3584ED69942E Q33605208-CB0A2597-2FB9-459F-9F54-041A34EB8541 Q33611180-219C82AE-2248-4D98-A280-7108C79C0482

P2860

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

http://www.wikidata.org/entity/Q44461877

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@en

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@nl

type

label

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@en

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@nl

prefLabel

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@en

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@nl

P1433

Q44461877-90D1F68A-42DB-4BFB-B7B4-02BA203327FF

P1476

Q44461877-272D4A81-DD4F-4DF3-8051-4A679985F87B

P2093

Q44461877-0068782A-ECC8-4C60-9732-39EDE1965345

Q44461877-08AC488C-667A-4085-A845-604D3C24E5E4

Q44461877-0B33E11B-5424-44F5-AAFA-3061693FB882

Q44461877-192473F7-2FDF-4289-BD1D-4610A285743C

Q44461877-2E8C6756-71E0-4425-BACD-C858FC05C980

Q44461877-35EC4CE2-8CE5-48F4-8163-1EE8DC580911

Q44461877-381C9A4A-DFB8-455D-9F8B-4931DE1007BD

Q44461877-3C21AC7F-0D2C-4ED6-A192-88CCE13CD4FF

Q44461877-568E3C1A-BE4B-41C3-A49D-8EE89BBF5EF1

Q44461877-7D18E2B9-95A0-4092-A6FD-6121BC013CDB

P304

Q44461877-F883965A-1183-4609-8B3B-AB90FF1361C3

P31

Q44461877-117E26CE-F56E-4F7C-AD5D-663968434BA3

P356

Q44461877-2ABDB4FA-E15C-4CD9-94C8-C7AA00A4B504

P407

Q44461877-707F1865-F035-4B7B-A397-F8725E68EF9F

P433

Q44461877-0E68FBB7-653D-482E-A2D5-82A2208B91C6

P478

Q44461877-ED5AD4AB-5E6A-4B06-8764-1A5592222AC0

P50

Q44461877-484CC183-3658-4B89-9F24-2A2E2DB05EEB

Q44461877-8F187E60-4132-4647-9686-835DE28F88B6

Q44461877-FE5222F2-2247-40F7-8448-ADCE4C766192

P577

Q44461877-95C41070-BEC0-40C7-B0B2-DAF99C28A5A6

P698

Q44461877-AFA2D9BE-8308-4401-A40B-BA852C3053C2

P921

Q44461877-45C98C1F-C12C-4BED-AACC-05EC593B9D72

Q44461877-A4D4BCFE-AEB6-46F7-8C7A-A222143EDD5D

P356

P1433

The New England Journal of Medicine

P1476

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

@en

P2093

Angel J Lacave

http://www.w3.org/2001/XMLSchema#string

Antonio Casado

http://www.w3.org/2001/XMLSchema#string

Cesar Mendiola

http://www.w3.org/2001/XMLSchema#string

Corneel Coens

http://www.w3.org/2001/XMLSchema#string

European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group

http://www.w3.org/2001/XMLSchema#string

Frédéric Amant

http://www.w3.org/2001/XMLSchema#string

Gavin C E Stuart

http://www.w3.org/2001/XMLSchema#string

Gunnar B Kristensen

http://www.w3.org/2001/XMLSchema#string

Leen Verleye

http://www.w3.org/2001/XMLSchema#string

Maria E L van der Burg

http://www.w3.org/2001/XMLSchema#string

P304

943-953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0908806

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Claes Göran Tropé

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20818904

http://www.w3.org/2001/XMLSchema#string

P921